**Supplemental Methods**

**eTable 1**. Study names, details, and participant information obtained from the OncoArray project1,2.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study Information** | | | | **Participants** | | | | **Genetic Ancestry** | | |  |  |  |  |
| **Abbreviation** | **Name** | **Location** | **Design** | **Controls** | **Any PCa** | **Aggressive PCa** | **Died of PCa** | **European** | **Asian** | **African** | **Known PCa Family History** | **PHS2 (median, IQR)** | **Age at PCa Diagnosis (median, IQR)** | **Age at Last Follow-up (median, IQR)** |
| Aarhus (n=1630) | Aarhus Prostate Cancer Study | Aarhus, Denmark | Hospital-based, observational | 550 | 1080 | 839 | 65 | 1621 | 9 | 0 | 856 | 0.4892 [0.2875, 0.7081] | 64.1 [59.8, 68.0] | 67.1 [62.3, 71.9] |
| AHS (n=1650) | Agricultural Health Study | Maryland, USA | Case-control (nested) within prospective cohort | 1159 | 491 | 238 | 23 | 1650 | 0 | 0% | 1572 | 0.4193 [0.2232, 0.6236] | 67.6 [61.8, 73.5] | 75.0 [69.0, 81.2] |
| ATBC (n=3117) | Alpha-Tocopherol Beta-Carotene | Maryland, USA | Prospective, nested case-control | 1910 | 1207 | 252 | 238 | 3117 | 0 | 0 | 2761 | 0.4649 [0.2686, 0.6628] | 72.0 [69.0, 76.0] | 78.6 [74.0, 82.6] |
| BioVU (n=204) | Vanderbilt University Biorepository | Nashville, USA | Hospital-based, case-control | 0 | 204 | 0 | 0 | 0 | 0 | 204 | 0 | 0.4768 [0.2658, 0.6174] | 61.0 [55.4, 66.5] | 61.0 [55.4, 66.5] |
| Canary PASS (n=373) | Prostate Active Surveillance Study | USA | Prospective, observational | 0 | 373 | 0 | 0 | 364 | 9 | 0 | 0 | 0.5186 [0.3357, 0.7402] | 63.0 [58.0, 67.0] | 63.0 [58.0, 67.0] |
| CCI (n=270) | CCI Prostate | Alberta, Canada | Hospital-based, case series | 0 | 270 | 71 | 1 | 266 | 4 | 0 | 0 | 0.5666 [0.381, 0.7521] | 64.3 [59.1, 68.7] | 69.8 [64.7, 75.5] |
| CeRePP (n=1755) | French Prostate Case Control Study | Paris, France | Case-control, prospective, hospital-based | 730 | 1025 | 805 | 13 | 1567 | 3 | 185 | 1748 | 0.4935 [0.2943, 0.6984] | 66.0 [60.0, 71.0] | 68.0 [61.0, 73.0] |
| CHIPGECS (n=1070) | Chinese Prostate Cancer Genetic and Environmental Correlation Study | China | Population-based, case-control, observational | 596 | 474 | 293 | 0 | 0 | 1070 | 0 | 0 | 0.3456 [0.1343, 0.5244] | 71.0 [65.0, 76.0] | 70.0 [63.0, 75.0] |
| COH (n=519) | City of Hope | Duarte, USA | Case-control | 259 | 260 | 192 | 0 | 516 | 3 | 0 | 260 | 0.496 [0.2931, 0.7019] | 62.0 [55.0, 65.0] | 61.0 [56.0, 66.1] |
| COSM (n=3282) | Cohort of Swedish Men | Stockholm, Sweden | Population-based cohort | 1117 | 2165 | 1404 | 278 | 3279 | 3 | 0 | 2455 | 0.4861 [0.2975, 0.6946] | 69.9 [64.6, 76.5] | 78.0 [72.3, 84.1] |
| CPCS1 (n=791) | Copenhagen Prostate Cancer Study 1 | Copenhagen, Denmark | Case-control | 256 | 535 | 433 | 8 | 790 | 1 | 0 | 0 | 0.4833 [0.2922, 0.692] | 68.1 [63.9, 72.6] | 70.4 [64.6, 76.2] |
| CPCS2 (n=667) | Copenhagen Prostate Cancer Study 2 | Copenhagen, Denmark | Case-control | 227 | 440 | 323 | 3 | 667 | 0 | 0 | 0 | 0.483 [0.284, 0.6848] | 64.4 [60.7, 67.7] | 67.8 [61.0, 71.7] |
| CPDR (n=176) | Center for Prostate Disease Research | USA | Retrospective | 41 | 135 | 38 | 0 | 0 | 0 | 176 | 153 | 0.4088 [0.2264, 0.5656] | 56.0 [50.7, 62.1] | 57.7 [52.7, 65.0] |
| EPIC (n=1328) | European Prospective Investigation Into Cancer and Nutrition (BPC3) | European Union | Case-control | 696 | 632 | 180 | 28 | 1324 | 4 | 0 | 0 | 0.4668 [0.2676, 0.6722] | 67.2 [62.7, 71.0] | 70.3 [65.2, 73.7] |
| EPICAP (n=29) | EPIdemiologcal study of Prostate CAncer | Hérault, France | Population-based, case-control | 9 | 20 | 15 | 3 | 0 | 0 | 29 | 18 | 0.47315 [0.2626, 0.583] | 64.6 [61.8, 68.6] | 64.9 [61.5, 68.5] |
| ERSPC (n=137) | Erasmus Medical Centre | Rotterdam, The Netherlands | Population-based, randomized control trial | 66 | 71 | 0 | 0 | 136 | 1 | 0 | 0 | 0.4597 [0.2111, 0.6343] | 71.0 [69.5, 73.2] | 71.1 [69.5, 73.1] |
| ESTHER (n=17) | Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population | Heidelberg, Germany | Population-based, prospective, case-control | 3 | 14 | 6 | 0 | 17 | 0 | 0 | 17 | 0.4385 [0.183, 0.5686] | 66.6 [64.8, 67.8] | 70.8 [67.8, 73.1] |
| FHCRC (n=812) | Fred Hutchinson Cancer Research Centre | Seattle, USA | Population-based, case control | 399 | 413 | 226 | 28 | 795 | 17 | 0 | 812 | 0.4739 [0.2901, 0.6608] | 60. [55.0, 66.0] | 68.0 [60.0, 75.4] |
| Gene-PARE (n=253) | Genetic Predictors of Adverse Radiotherapy Effects | New York, USA and Tokyo/Chiba, Japan | Hospital-based | 0 | 253 | 125 | 0 | 242 | 11 | 0 | 0 | 0.56415 [0.3733, 0.73184] | 66.3 [61.3, 71.8] | 75.3 [69.1, 79.8] |
| Hamburg-Zagreb (n=295) | Hamburg-Zagreb | Hamburg, Germany | Hospital-based, prospective | 149 | 146 | 112 | 10 | 295 | 0 | 0 | 267 | 0.4992 [0.2738, 0.6679] | 68.3 [62.3, 74.0] | 62.0 [54.0, 73.4] |
| HPFS (n=2221) | Health Professionals Follow-up Study | Boston, USA | Nested case-control | 1050 | 1171 | 581 | 75 | 2212 | 9 | 0 | 368 | 0.4676 [0.2646, 0.6534] | 70.0 [65.0, 75.0] | 79.7 [73.7, 84.7] |
| IMPACT (n=925) | Identification of Men with a genetic predisposition to ProstAte Cancer | The ICR, London, UK | Observational | 875 | 50 | 24 | 0 | 915 | 10 | 0 | 925 | 0.433 [0.2271, 0.6234] | 64.3 [61.0, 67.3] | 57.3 [49.9, 64.7] |
| IPO-Porto (n=551) | Portuguese Oncology Institute | Porto, Portugal | Hospital-based | 180 | 371 | 276 | 1 | 551 | 0 | 0 | 371 | 0.547 [0.3052, 0.7734] | 55.0 [52.0, 61.0] | 60.0 [54.0, 65.4] |
| KARUPROSTATE (n=749) | French West Indies Prostate Cancer Study | French West Indies | Case-control | 386 | 363 | 226 | 0 | 0 | 0 | 749 | 735 | 0.3629 [0.2113, 0.5466] | 66.7 [61.0, 72.0] | 63.5 [57.3, 70.2] |
| KULEUVEN (n=269) | Katholieke Universiteit Leuven | Leuven, Belgium | Hospital-based, prospective, observational | 103 | 166 | 149 | 8 | 269 | 0 | 0 | 40 | 0.4419 [0.2169, 0.6643] | 66.9 [60.4, 71.0] | 74.3 [68.5, 80.2] |
| LAAPC (n=732) | Los Angeles Study of Aggressive Prostate Cancer | California, USA | Population-based, case control | 285 | 447 | 0 | 0 | 720 | 12 | 0 | 0 | 0.4691 [0.274, 0.6769] | 67.0 [60.0, 74.0] | 66.0 [58.0, 73.0] |
| Malaysia (n=405) | Malaysia | Malaysia | Case-control | 202 | 203 | 175 | 18 | 1 | 404 | 0 | 392 | 0.4113 [0.2112, 0.6088] | 70.5 [65.4, 75.5] | 75.2 [71.1, 79.5] |
| MCC-Spain (n=922) | Multi Case-Control Study-Spain | Barcelona, Spain | Case-control | 399 | 523 | 356 | 7 | 917 | 5 | 0 | 879 | 0.5136 [0.3101, 0.7001] | 66.7 [61.7, 72.2] | 70.3 [64.5, 76.0] |
| MCCS (n=1033) | Melbourne Collaborative Cohort Study | Melbourne, Australia | Nested case-control | 315 | 718 | 374 | 81 | 1030 | 3 | 0 | 134 | 0.5062 [0.2991, 0.7209] | 69.2 [65.0, 74.4] | 79.2 [73.9, 84.0] |
| MDACC\_AS (n=535) | MD Anderson Cancer Center Active Surveillance Trial | Texas, USA | Prospective, cohort | 0 | 535 | 151 | 0 | 501 | 34 | 0 | 534 | 0.5305 [0.3522, 0.7361] | 64.9 [58.6, 70.3] | 64.9 [58.6, 70.3] |
| MEC (n=1298) | Multiethnic Cohort Study | California / Hawaii, USA | Population-based | 670 | 628 | 0 | 29 | 1240 | 58 | 0 | 1231 | 0.4677 [0.2608, 0.6595] | 69.8 [64.2, 75.3] | 79.5 [73.4, 84.7] |
| MIAMI-WFPCS (n=108) | Miami-Wake Forest Prostate Cancer Study | North Carolina, USA | Case-control | 49 | 59 | 25 | 0 | 0 | 0 | 108 | 107 | 0.3724 [0.2112, 0.5631] | 60.4 [54.8, 65.0] | 58.1 [53.0, 64.4] |
| MOFFITT (n=797) | Moffitt Prostate Cancer Study | Florida, USA | Hospital-based | 296 | 501 | 268 | 4 | 596 | 9 | 192 | 794 | 0.4863 [0.2998, 0.677] | 64.0 [58.7, 69.4] | 64.1 [57.3, 71.3] |
| NMHS (n=364) | Nashville Men's Health Study | Nashville, USA | Clinic-based, case-control | 188 | 176 | 95 | 0 | 0 | 0 | 364 | 364 | 0.4022 [0.2099, 0.5637] | 64.0 [57.0, 69.0] | 63.0 [57.0, 68.0] |
| Oslo (n=1453) | Oslo University Hospital / General Cohort of Adults in Norway (CONOR) | Oslo, Norway | Population-based, observational | 0 | 1453 | 51 | 764 | 1443 | 10 | 0 | 0 | 0.5692 [0.3692, 0.7409] | 72.9 [66.5, 78.4] | 79.2 [73.0, 84.3] |
| PCaP (n=967) | North Carolina-Louisiana Prostate Cancer Project | North Carolina / Louisiana, USA | Population-based cohort | 0 | 967 | 432 | 0 | 0 | 0 | 967 | 967 | 0.4407 [0.2784, 0.601] | 62.0 [56.0, 68.0] | 62.0 [56.0, 68.0] |
| PCMUS (n=281) | Prostate Cancer Study Medical University Sofia | Sofia, Bulgaria | Case-control | 89 | 192 | 171 | 0 | 281 | 0 | 0 | 252 | 0.4976 [0.3215, 0.7323] | 68.0 [63.0, 74.0] | 67.9 [62.0, 74.0] |
| PHS (n=898) | Physicians Health Study | Harvard, Boston, USA | Nested case-control | 267 | 631 | 375 | 115 | 878 | 20 | 0 | 70 | 0.4947 [0.2983, 0.7133] | 68.5 [63.5, 73.5] | 82.7 [77.8, 87.3] |
| PLCO (n=1657) | Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial | Bethesda, USA | Nested case-control | 980 | 677 | 389 | 8 | 1657 | 0 | 0 | 1629 | 0.4371 [0.253, 0.6419] | 72.0 [68.0, 76.0] | 74.0 [70.0, 78.0] |
| Poland (n=801) | The Poland Group | Szczecin, Poland | Case-control | 317 | 484 | 373 | 0 | 800 | 1 | 0 | 437 | 0.5143 [0.3311, 0.7036] | 69.0 [63.0, 76.0] | 67.9 [61.0, 74.9] |
| PRAGGA (n=232) | Prostate cAncer Genetics in Galicia | Galicia, Spain | Case-control | 102 | 130 | 88 | 6 | 229 | 3 | 0 | 204 | 0.4896 [0.3285, 0.7238] | 68.9 [64.6, 72.3] | 73.2 [62.8, 78.8] |
| PROCAP (n=868) | PROgression in Cancer of the Prostate | Stockholm, Sweden | Population-based, observational | 241 | 627 | 310 | 215 | 862 | 6 | 0 | 0 | 0.5326 [0.317, 0.739] | 65.3 [61.3, 68.5] | 74.9 [69.2, 79.2] |
| PROFILE (n=35) | Genetic prostate cancer risk stratification for targeted screening | The ICR, London, UK | Hospital-based, observational, prospective | 22 | 13 | 7 | 0 | 34 | 1 | 0 | 35 | 0.4871 [0.2868, 0.6777] | 61.1 [53.7, 66.8] | 57.1 [48.6, 63.0] |
| PROGReSS (n=996) | Prostate cancer: Mechanisms of Progression and Treatment | Santiago de Compostela, Spain | Hospital-based, observational, prospective | 322 | 674 | 465 | 21 | 995 | 1 | 0 | 174 | 0.5012 [0.3041, 0.6955] | 71.0 [64.7, 75.1] | 74.2 [65.5, 79.2] |
| ProMPT (n=798) | Prostate Cancer: Mechanisms of Progression and Treatment | Cambridge, UK | Population-based | 12 | 786 | 627 | 37 | 791 | 7 | 0 | 156 | 0.5924 [0.4041, 0.809] | 64.5 [60.0, 69.2] | 68.2 [63.6, 73.6] |
| ProtecT (n=1419) | Prostate Testing for Cancer and Treatment | Oxford, Bristol, and Cambridge, UK | Population-based cohort | 1415 | 4 | 0 | 0 | 1413 | 6 | 0 | 1242 | 0.4101 [0.1987, 0.5984] | 64.1 [60.7, 67.9] | 61.4 [57.2, 65.4] |
| PROtEuS (n=123) | The Prostate Cancer and Environment Study | Montreal, Canada | Population-based, case-control | 53 | 70 | 45 | 0 | 0 | 0 | 123 | 118 | 0.4057 [0.2222, 0.572] | 63.5 [57.2, 66.5] | 63.9 [59.4, 68.6] |
| QLD (n=4564) | Queensland Study | Brisbane, Australia | Case-control | 1252 | 3312 | 2680 | 53 | 4504 | 60 | 0 | 2165 | 0.526 [0.3248, 0.7249] | 62.7 [57.8, 67.2] | 66.1 [60.4, 71.5] |
| RAPPER (n=2117) | Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy | Manchester, UK | Hospital-based, prospective | 0 | 2117 | 0 | 0 | 2100 | 17 | 0 | 0 | 0.573 [0.3838, 0.7748] | 70.6 [66.0, 74.7] | 70.6 [66.0, 74.7] |
| SABOR (n=211) | San Antonio Center of Biomarkers of Risk for Prostate Cancer | San Antonio, USA | Population-based cohort | 106 | 105 | 37 | 0 | 0 | 0 | 211 | 0 | 0.4537 [0.2669, 0.6288] | 63.3 [55.8, 70.2] | 63.6 [55.9, 70.4] |
| SCCS (n=1789) | Southern Community Cohort Study | Southeastern USA | Population-based cohort | 1498 | 291 | 20 | 0 | 0 | 0 | 1789 | 1665 | 0.3858 [0.2208, 0.5602] | 58.0 [53.0, 64.0] | 60.0 [53.0, 67.0] |
| SCPCS (n=89) | South Carolina Prostate Cancer Study | South Carolina, USA | Population-based, case control, observational | 32 | 57 | 26 | 0 | 0 | 0 | 89 | 89 | 0.4141 [0.2064, 0.5879] | 71.0 [68.0, 75.0] | 70.0 [67.0, 74.0] |
| SEARCH (n=2669) | Study of Epidemiology and Risk factors in Cancer Heredity | Cambridge, UK | Case-control | 232 | 2437 | 1549 | 148 | 2637 | 32 | 0 | 1519 | 0.5569 [0.3672, 0.76] | 64.0 [61.0, 67.0] | 70.8 [66.6, 74.0] |
| SFPCS (n=602) | San Francisco Prostate Cancer Study | California, USA | Population-based, case control, observational | 241 | 361 | 55 | 50 | 484 | 1 | 117 | 602 | 0.4776 [0.2926, 0.6781] | 65.0 [58.6, 71.0] | 69.1 [62.6, 76.0] |
| SNP\_Prostate\_Ghent (n=451) | SNP Prostate Ghent | Ghent, Belgium | Hospital-based, observational | 135 | 316 | 243 | 1 | 451 | 0 | 0 | 393 | 0.5033 [0.2725, 0.7168] | 65.4 [60.6, 70.3] | 68.8 [62.8, 75.0] |
| SPAG (n=211) | Serum Proteomic analysis for biomarkers of Aggressive prostate disease in the Guernsey population | Manchester / Southampton, UK | Hospital-based, observational | 172 | 39 | 30 | 1 | 210 | 1 | 0 | 10 | 0.4637 [0.2589, 0.658] | 66.1 [62.1, 68.5] | 68.6 [62.8, 74.4] |
| STHM2 (n=4524) | Stockholm 2 | Stockholm, Sweden | Population-based, observational | 1491 | 3033 | 1562 | 96 | 4497 | 27 | 0 | 0 | 0.5051 [0.3035, 0.6941] | 65.6 [60.9, 70.1] | 69.7 [64.6, 74.5] |
| SWOG-PCPT (n=2409) | Prostate Cancer Prevention Trial | Seattle, USA | Case-control from randomized trial | 1273 | 1136 | 338 | 0 | 2154 | 91 | 164 | 2409 | 0.4246 [0.2374, 0.6161] | 69.0 [65.0, 74.0] | 74.4 [70.0, 79.8] |
| SWOG-SELECT (n=3849) | Selenium and Vitamin E Cancer Prevention Trial | Seattle, USA | Case-control from randomized trial | 2307 | 1542 | 561 | 10 | 3541 | 111 | 197 | 3848 | 0.4448 [0.2441, 0.6349] | 67.0 [63.0, 71.0] | 67.0 [62.0, 73.0] |
| TAMPERE (n=3591) | Finnish Genetic Predisposition to Prostate Cancer Study | Tampere, Finland | Population-based, case-control, observational | 1179 | 2412 | 1478 | 146 | 3585 | 6 | 0 | 134 | 0.5107 [0.3098, 0.7065] | 67.1 [62.8, 71.3] | 73.6 [69.5, 78.0] |
| TORONTO (n=1276) | Toronto | Toronto, Canada | Prospective, hospital-based cohort | 544 | 732 | 411 | 0 | 1123 | 153 | 0 | 1166 | 0.4956 [0.2958, 0.6852] | 65.0 [60.2, 70.6] | 63.8 [58.3, 69.3] |
| UKGPCS (n=11021) | U.K. Genetic Prostate Cancer Study and The Prostate Cancer Research Foundation Study | United Kingdom | Hospital-based | 2973 | 8048 | 5107 | 1378 | 10514 | 142 | 365 | 7772 | 0.5358 [0.3319, 0.7445] | 58.7 [55.2, 63.6] | 66.0 [61.7, 73.0] |
| ULM (n=408) | Institut fuer Humangengetik Ulm | Ulm, Germany | Case-control | 3 | 405 | 307 | 13 | 407 | 1 | 0 | 408 | 0.5654 [0.3859, 0.7537] | 65.0 [60.0, 70.3] | 68.6 [63.1, 74.0] |
| WUGS (n=898) | Washington University Genetics Study | St. Louis, USA | Case series, hospital-based | 152 | 746 | 430 | 0 | 668 | 6 | 224 | 773 | 0.5091 [0.3173, 0.7336] | 62.0 [56.0, 67.0] | 64.0 [57.0, 69.0] |
| **Overall (n=80491)** |  |  |  | **30575** | **49916** | **26419** | **3983** | **71856** | **2382** | **6253** | **46030** | **0.4908 [0.2910, 0.6908]** | **65.3 [59.6, 71.0]** | **70.0 [63.4, 76.5]** |

Genetic Ancestry

Genetic ancestry for men included in the present dataset was previously determined. Briefly, genetic data from 2,318 ancestry informative markers were mapped into a two-dimensional space representing the first two principal components. The distance from the individual’s mapping to the three reference clusters (European, African, and Asian) was then used to estimate the individual’s genetic ancestry2,3. Individuals were subsequently classified into one of three labels; European: greater than 80% European ancestry, Asian: greater than 40% Asian ancestry, and African: greater than 20% African ancestry. A comparison of self-reported race/ethnicity and determined genetic ancestry is shown in eTable 2.

**eTable 2**. Self-reported race/ethnicity and genetic ancestry for individuals in the dataset (n=80,491).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Self-reported Race/Ethnicity** | **Number** | **Genetic Ancestry** | | |
| **European** | **Asian** | **African** |
| European | 63,954 | 63,685 | 250 | 19 |
| East Asian | 1,212 | 21 | 1,190 | 1 |
| African American | 5,920 | 19 | 9 | 5,892 |
| Hawaiian | 154 | 138 | 16 | 0 |
| Hispanic American | 326 | 139 | 176 | 11 |
| South Asian | 167 | 17 | 150 | 0 |
| Black African | 84 | 5 | 3 | 76 |
| Black Caribbean | 243 | 5 | 4 | 234 |
| Other/Unknown | 8,431 | 7,827 | 584 | 20 |

Adapting the PHS to OncoArray: Proxy SNP Identification

To identify proxy single-nucleotide polymorphisms (SNPs) for those not directly genotyped on OncoArray, we identified samples from 12,107 men of European genetic ancestry that were genotyped on both the iCOGs array and OncoArray, within the PRACTICAL consortium. We searched for proxy SNPs (on the same chromosome as the original SNP and within 106 base pairs of the original SNP) with linkage disequilibrium r2≥0.90. Since a suitable proxy could not be identified on OncoArray for all 30 missing SNPs, we re-calculated the *β* parameter estimates for a Cox proportional hazards regression, using the same dataset used for the initial development of PHS1. That development dataset includes 18,868 prostate cancer cases and 12,879 controls and has been described previously4.

PHS percentile thresholds

Percentiles of PHS2 were determined from the original reference dataset for PHS1 (i.e., controls in the development set with age <70 years4). Percentiles for PHS2 are shown in eTable 3.

**eTable 3**. Percentile thresholds of PHS2.

|  |  |
| --- | --- |
| **Percentile** | **PHS2** |
| 20th | 0.1603 |
| 50th | 0.3949 |
| 80th | 0.6521 |
| 98th | 0.9966 |

Sample-Weight Correction and Sensitivity Analysis

In order to appropriately calculate the sample-weight corrections, we needed prostate cancer age-specific incidence rates at a population level. We were able to obtain such information for the following countries: the USA5, Sweden6–9, Norway6,7, Finland6,7, Denmark6,7, the UK10, and Australia11. While the incidence rates in each age range varied between countries (likely a reflection of screening prevalence and differing policies for prostate cancer screening in each population), the pattern was relatively similar, and typically varied by a factor of less than 2-3 for each 5-year age bin. Sweden was chosen as a representative population with published raw numbers of men diagnosed with prostate cancer8,9 and of total men in the age range of 45-79 years. Published Swedish Cancer Registry and Swedish population data reported there were 9,024 prostate cancer cases and 1,953,203 men without prostate cancer aged 45-79 in 20168,9.  We used these numbers to correct for sampling bias12,13 for all Cox proportional hazards regressions reported; calculations were made using the R “survival” package14.

Given that the overall incidence of prostate cancer in different populations varies, and the current dataset comes from a multi-institutional and multi-national dataset, we performed a sensitivity analysis for the above population numbers. This was done by adjusting the assumed population prostate cancer incidence by a factor of up to four times lesser or greater than that of Sweden, then re-calculating the corrected hazard ratios (HRs) for PHS associations with PCa. The range of incidence in the sensitivity analyses (25% to 400% of the Swedish incidence) is wider than the range across the countries mentioned above and wider than the range reported for ethnicity-related variation15,16. We calculated each HR of interest (HR20/50, HR80/50, HR98/50, and HR80/20), for the association of PHS with any PCa, aggressive PCa, and death from PCa (in the multi-ethnic dataset and by each genetic ancestry group, where applicable) to determine how changes in assumed population incidence affected the calculated HRs.

**Supplemental Results**

SNPs included in PHS2

**eTable 4.** SNP identifier, chromosome, effect allele, reference allele, and position (based on version 37) and beta (model weight) for the 46 SNPs used in PHS2 calculation\*.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ID | Chromosome | Effect | Reference | Position | PHS2beta |
| chr2\_63301164 | 2 | A | G | 63301164 | -0.069 |
| chr2\_85808982 † | 2 | G | A | 85808982 | -0.049 |
| rs16860513 | 2 | T | A | 173342367 | -0.198 |
| chr3\_87147922 | 3 | T | A | 87147922 | 0.123 |
| rs6788616 | 3 | G | A | 87205079 | 0.041 |
| rs4857841 † | 3 | A | G | 128046643 | 0.031 |
| rs78416326 | 3 | G | C | 170074517 | -0.080 |
| chr4\_95544718 | 4 | G | A | 95544718 | 0.053 |
| rs17021918 § | 4 | A | G | 95562877 | -0.026 |
| rs7679673 § | 4 | A | C | 106061534 | -0.071 |
| rs7725218 | 5 | A | G | 1282414 | -0.078 |
| rs2736108 | 5 | A | G | 1297488 | 0.056 |
| rs10866527 | 5 | A | G | 1891800 | 0.045 |
| rs3910736 | 6 | A | G | 153412476 | -0.073 |
| rs7769879 | 6 | C | G | 160865645 | 0.053 |
| rs6965016 † | 7 | C | A | 97807882 | 0.049 |
| chr8\_23525358 † | 8 | G | A | 23525358 | 0.062 |
| rs9297746 | 8 | G | A | 127909361 | -0.061 |
| rs28556804 | 8 | G | A | 128014315 | -0.074 |
| chr8\_128077146 | 8 | A | G | 128077146 | 0.200 |
| rs1016343 | 8 | A | G | 128093297 | 0.073 |
| rs60163266 | 8 | A | G | 128323157 | 0.073 |
| rs6983267 § | 8 | A | C | 128413305 | -0.100 |
| rs7812894 † | 8 | T | A | 128520479 | 0.084 |
| rs12549761 | 8 | G | C | 128540776 | -0.065 |
| rs10993994 § | 10 | A | G | 51549496 | 0.106 |
| rs72853963 | 11 | A | G | 2224664 | 0.071 |
| rs12275055 | 11 | G | A | 68981359 | 0.083 |
| chr11\_68985583 † | 11 | G | A | 68985583 | -0.047 |
| rs11568818 § | 11 | G | A | 102401661 | -0.047 |
| rs10875943 § | 12 | G | A | 49676010 | 0.036 |
| chr12\_53282274 | 12 | A | C | 53282274 | 0.050 |
| rs4643253 | 14 | G | A | 69106108 | -0.049 |
| rs684232 § | 17 | G | A | 618965 | 0.042 |
| rs718961 | 17 | A | G | 36077099 | -0.074 |
| rs11651052 † | 17 | A | G | 36102381 | -0.094 |
| chr17\_46820676 | 17 | A | G | 46820676 | 0.138 |
| rs9889335 † | 17 | A | C | 69115146 | 0.082 |
| rs11672691 § | 19 | A | G | 41985587 | -0.062 |
| chr19\_51361757 | 19 | G | A | 51361757 | -0.160 |
| chr20\_62233638 | 20 | G | A | 62233638 | -0.049 |
| chr22\_43501620 | 22 | G | A | 43501620 | -0.081 |
| chr22\_43503547 | 22 | G | A | 43503547 | -0.047 |
| rs4907775 † | 23 | G | A | 51263200 | 0.056 |
| chrX\_66751555 | 23 | G | A | 66751555 | -0.047 |
| rs11795627 | 23 | A | G | 69957441 | -0.040 |

\* Comparing the 46 SNPs included in PHS2 and the 147 SNPs identified in a recent meta-analysis of men with European ancestry1, there were 8 PHS2 SNPs that were exact matches (§) and 9 PHS2 SNPs in linkage disequilibrium (> 0.90, among men with European ancestry in the present study) (†) with one of the 147 meta-analysis SNPs.

**eTable 5:Summary statistics for PHS2.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Genetic Ancestry** | | | |
| **PHS2 Summary Statistics** | **All** | **European** | **Asian** | **African** |
| Median PHS2(IQR) | 0.49 (0.29, 0.69) | 0.50 (0.30, 0.70) | 0.41 (0.21, 0.60) | 0.41 (0.24, 0.57) |
| Median PHS2(IQR) in controls | 0.39 (0.20, 0.58) | 0.40 (0.21, 0.59) | 0.34 (0.14, 0.52) | 0.37 (0.20, 0.54) |
| Median PHS2(IQR) in participants diagnosed with any prostate cancer | 0.55 (0.36, 0.75) | 0.56 (0.37, 0.76) | 0.47 (0.27, 0.68) | 0.43 (0.27, 0.60) |
| Median PHS2(IQR) in participants diagnosed with aggressive prostate cancer | 0.55 (0.36, 0.75) | 0.56 (0.37, 0.76) | 0.46 (0.25, 0.67) | 0.42 (0.27, 0.59) |
| Median PHS2(IQR) in participants who died of prostate cancer | 0.56 (0.37, 0.76) | 0.56 (0.37, 0.75) | 0.51 (0.28, 0.74) | 0.44 (0.31, 0.53) |
| Median PHS2(IQR) in participants who did not die of prostate cancer | 0.49 (0.29, 0.69) | 0.50 (0.30, 0.70) | 0.40 (0.21, 0.59) | 0.41 (0.24, 0.57) |

Sensitivity Analysis: Any Prostate Cancer

**eTable 6:** Results of the sensitivity analysis for PHS association with any prostate cancer in the multi-ethnic dataset, and by genetic ancestry group. Results are the maximum deviation in each HR when the assumed population incidence was varied over a range of values, from 25% to 400% of that reported in Sweden. Each HR was within 2.5% of those reported in the manuscript, even with a 4-fold change (lesser or greater) in the assumed population incidence.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Maximum deviation of HRscomparing percentiles of PHS2 for prediction of age of onset of aggressive prostate cancer** | | | |
| ***Genetic ancestry*** | **HR20/50:**  **≤20th vs 30-70th** | **HR80/50:**  **≥80th vs 30-70th** | **HR98/50:**  **≥98th vs 30-70th** | **HR80/20:**  **≥80th vs ≤20th** |
| **All (n=80,491)** | 1.1% | 1.2% | 1.9% | 2.2% |
| **European (n=71,856)** | 1.0% | 1.1% | 1.8% | 2.0% |
| **Asian (n=2,382)** | 1.2% | 1.3% | 2.1% | 2.5% |
| **African (n=6,253)** | 1.2% | 1.1% | 2.0% | 2.2% |

Sensitivity Analysis: Aggressive Prostate Cancer

**eTable 7:** Results of the sensitivity analysis for PHS association with aggressive prostate cancer in the multi-ethnic dataset, and by genetic ancestry group. Results are the maximum deviation in each HR when the assumed population incidence was varied over a range of values, from 25% to 400% of that reported in Sweden. Each HR was within 2.3% of those reported in the manuscript, even with a 4-fold change (lesser or greater) in the assumed population incidence.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Maximum deviation of HRscomparing percentiles of PHS2 for prediction of age of onset of aggressive prostate cancer** | | | |
| ***Genetic ancestry*** | **HR20/50:**  **≤20th vs 30-70th** | **HR80/50:**  **≥80th vs 30-70th** | **HR98/50:**  **≥98th vs 30-70th** | **HR80/20:**  **≥80th vs ≤20th** |
| **All (n=58,600)** | 1.1% | 1.2% | 1.9% | 2.2% |
| **European (n=53,608)** | 1.0% | 1.1% | 1.7% | 2.0% |
| **Asian (n=1,806)** | 1.1% | 1.2% | 2.0% | 2.3% |
| **African (n=3,186)** | 1.1% | 1.1% | 1.9% | 2.2% |

Sensitivity Analysis: Death from Prostate Cancer

**eTable 8**: Results of the sensitivity analysis for PHS association with fatal prostate cancer in the multi-ethnic dataset. Results are the maximum deviation in each HR when the assumed population incidence was varied over a range of values, from 25% to 400% of that reported in Sweden. Each HR was within 3.7% of those reported in the manuscript, even with a 4-fold change (lesser or greater) in the assumed population incidence.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Maximum percent deviation of HRscomparing percentiles of PHS2 for prediction of age of prostate cancer death** | | | |
| ***Genetic ancestry*** | **HR20/50:**  **≤20th vs 30-70th** | **HR80/50:**  **≥80th vs 30-70th** | **HR98/50:**  **≥98th vs 30-70th** | **HR80/20:**  **≥80th vs ≤20th** |
| **All (n=78,221)** | 1.8% | 1.9% | 3.2% | 3.7% |

PHS and Family History: Age at Diagnosis of Aggressive Prostate Cancer

**eTable 9**: Multivariable models with both PHS and family history of prostate cancer (≥1 first-degree relative affected, binary) for association with aggressive prostate cancer in the multi-ethnic dataset, and by genetic ancestry. This analysis is limited to individuals with known family history. Both family history and PHS were significantly associated with aggressive prostate cancer in the combined models. Hazard ratios (HR) for family history were calculated as the exponent of the beta from the multivariable Cox proportional hazards regression17. The HR for PHS in the multivariable models was estimated as the HR80/20 (men in the highest 20% vs. those in the lowest 20% of genetic risk by PHS2) in each cohort. The model with PHS performed better than family history alone (log-likelihood *p*<10-16).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***Genetic Ancestry*** | **Variable** | **beta** | ***z*-score** | **p-value** | **HR** |
|  | | | | |  |
| **All (n=35,852)** | PHS | 2.2 | 48 | <10-16 | 5.1 |
| Family History | 0.9 | 31 | <10-16 | 2.5 |
|  | | | | |  |
| **European (n=32,019)** | PHS | 2.1 | 47 | <10-16 | 4.9 |
| Family History | 0.9 | 31 | <10-16 | 2.5 |
|  | | | | |  |
| **Asian (n=902)** | PHS | 1.7 | 38 | <10-16 | 3.6 |
| Family History | 0.3 | 7 | <10-10 | 1.4 |
|  | | | | |  |
| **African (n=2,931)** | PHS | 1.1 | 22 | <10-16 | 2.2 |
| Family History | 0.9 | 32 | <10-16 | 2.6 |

PHS and Family History: Age of Death from Prostate Cancer

**eTable 10:** Multivariable models with both PHS and family history (binary) for association with fatal prostate cancer in the multi-ethnic dataset. This analysis is limited to individuals with known family history (n=46,030). Both family history and PHS were significantly associated with prostate cancer death in the combined model. The hazard ratio (HR) for family history was calculated as the exponent of the beta from the multivariable Cox proportional hazards regression. Among those with known family history, the combination of family history and PHS performed better than family history alone (log-likelihood *p*<10-16).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***Genetic Ancestry*** | **Variable** | **beta** | **z-score** | **p-value** | **HR** |
|  | | | | |  |
| **All (n=46,030)** | PHS | 2.2 | 16 | <10-16 | 5.3 |
| Family History | 0.8 | 8 | <10-16 | 2.2 |

**References from Supplemental Material**

1. Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2018;50(7):928-936. doi:10.1038/s41588-018-0142-8

2. Amos CI, Dennis J, Wang Z, et al. The OncoArray consortium: A network for understanding the genetic architecture of common cancers. *Cancer Epidemiol Biomarkers Prev*. 2017;26(1):126-135. doi:10.1158/1055-9965.EPI-16-0106

3. Li Y, Byun J, Cai G, et al. FastPop: A rapid principal component derived method to infer intercontinental ancestry using genetic data. *BMC Bioinformatics*. 2016;17(1). doi:10.1186/s12859-016-0965-1

4. Seibert TM, Fan CC, Wang Y, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: Development and validation in large scale cohorts. *BMJ*. 2018;360:1-7. doi:10.1136/bmj.j5757

5. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds). SEER Cancer Statistics Review, 1975-2015. National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975\_2015/. Accessed March 5, 2019.

6. Engholm G, Ferlay J, Christensen N, et al. NORDCAN - A Nordic tool for cancer information, planning, quality control and research. *Acta Oncol (Madr)*. 2010;49(5):725-736. doi:10.3109/02841861003782017

7. Engholm G, Ferlay J, Christensen N, et al. Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries. Danish Cancer Society. http://www.ancr.nu. Accessed September 18, 2018.

8. Statistics Sweden. Population statistics. https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/. Accessed March 5, 2019.

9. Socialstyrelsen - The National Board of Health and Welfare. Statistics on Cancer Incidence 2016. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2017-12-31.pdf. Accessed March 5, 2019.

10. Cancer Research UK. Prostate cancer incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence. Accessed August 15, 2018.

11. Australian Institute of Health and Welfare. *2017 Australian Cancer Incidence and Mortality (ACIM) Books: Prostate Cancer*. Canberra: AIHW.: http://www.aihw.gov.au/acim-books

12. Therneau TM, Li H. Computing the Cox Model for Case Cohort Designs. *Lifetime Data Anal*. 1999;5(2):99-112. doi:10.1023/A:1009691327335

13. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. New York: Springer; 2000.

14. R Core Team. R: A language and environment for statistical computing. In: *Vienna, Austria: R Foundation for Statistical Computing*. ; 2015.

15. Rebbeck TR. Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. *Semin Radiat Oncol*. 2017;27(1):3-10. doi:10.1016/j.semradonc.2016.08.002

16. Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. *Am J Mens Health*. 2018;12(6):1807-1823. doi:10.1177/1557988318798279

17. Klein JP, Houwelingen HC, Ibrahim JG ST, ed. *Handbook of Survival Analysis*. London: Chapman and Hall/CRC; 2013.